Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA 505(b)(2) Policy Affirmed; Any Changes Will Be Too Late For Norvasc

Executive Summary

FDA will reconsider whether approval of new salt formulations under the Sec. 505(b)(2) process is appropriate, but any changes will not prevent approval of a pending competitor to Pfizer's antihypertensive Norvasc

You may also be interested in...



Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor

FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway

Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor

FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway

Apotex Challenges FDA “Shared” Generic Exclusivity Policy In Paxil Suit

TorPharm is challenging FDA's policy of awarding "shared" 180-day marketing exclusivity to multiple generic companies

Related Content

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel